Actuate Therapeutics Says Elraglusib Demonstrated Anti-Tumor Activity with Two Ongoing Durable Complete Responses And ~62% Disease Control Rate In First 8 Patients With Relapsed/Refractory Ewing And Ewing-related Sarcomas
Portfolio Pulse from Benzinga Newsdesk
Actuate Therapeutics announced that its drug Elraglusib showed promising results in treating relapsed/refractory Ewing and Ewing-related sarcomas. In the first 8 patients, the drug achieved a 62% disease control rate and two ongoing durable complete responses.
September 09, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actuate Therapeutics reported positive results for its drug Elraglusib in treating Ewing sarcomas, achieving a 62% disease control rate and two complete responses in early trials.
The positive trial results for Elraglusib could boost investor confidence in Actuate Therapeutics, potentially leading to a short-term increase in stock price. The 62% disease control rate and complete responses are significant achievements in early-stage trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100